<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082173</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-002135-01</org_study_id>
    <nct_id>NCT00082173</nct_id>
  </id_info>
  <brief_title>Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis</brief_title>
  <official_title>Phase 2 Randomized Trial of a Moxifloxacin-Containing Regimen For Treatment of Smear-Positive Pulmonary Tuberculosis in Adults With and Without HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and
      then two drugs for 4 months. New drug regimens that are shorter and effective against
      drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin
      (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will effectively
      treat TB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately one-third of the world's population is infected with Mycoplasma tuberculosis; 7
      to 8 million new cases of active TB occur each year. TB is the second most common infectious
      cause of death worldwide. Appropriate treatment of persons with active TB is very important
      in limiting the transmission of M. tuberculosis and preventing TB-related mortality. Current
      therapy requires 6 months of a four-drug regimen of isoniazid (INH), rifampin (RIF),
      pyrazinamide (PZA), and EMB.

      The development of alternative regimens is a priority, and new classes of antituberculosis
      agents are needed to provide treatment options for patients with drug-resistant disease. This
      study will evaluate the effectiveness of replacing EMB with MOX in a multi-drug regimen in
      the initial phase of treatment of smear-positive pulmonary TB in patients with and without
      HIV infection.

      Participants in this study will be randomly assigned to receive either a MOX-containing drug
      regimen or the standard EMB-containing drug regimen for 8 weeks. Participants will have study
      visits weekly during these 8 weeks. After 8 weeks, participants will discontinue MOX, EMB,
      and PZA and will continue taking INH and RFP for 4 months. Participants will have study
      visits at Months 4, 6, 12, and 18. Study visits will include a medical interview, physical
      exam, blood and urine tests, and sputum tests for TB.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Sterile Sputum Cultures</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients with sterile sputum cultures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients with Grade 3 or 4 adverse reactions attributable to study medications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400mg daily for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presumptive diagnosis of smear-positive pulmonary TB within 2 weeks of study entry.
             Patients with both pulmonary and extrapulmonary disease are eligible.

          -  Documentation of HIV infection status. If HIV status is unknown at study entry, the
             participant must consent to testing and results must be available prior to study
             participation.

          -  Agree to use acceptable methods of contraception

        Exclusion Criteria:

          -  History of adverse drug reaction to MOX, INH, RIF, PZA, or EMB

          -  Disease or condition for which MOX, INH, RIF, PZA, or EMB is contraindicated

          -  History of more than 14 days of continuous antituberculosis therapy during the
             previous 2 years or more than 2 months of antituberculosis therapy ever

          -  Active AIDS-related opportunistic infection or malignancy

          -  Currently receiving or planning to receive HIV protease inhibitors or nonnucleoside
             reverse transcriptase inhibitors in the first 2 months after study entry

          -  Silicotuberculosis

          -  Central nervous system TB

          -  Pregnant or breastfeeding

          -  Unable to take oral medication

          -  Electrocardiogram (EKG) QTc interval greater than 450 msec

          -  Taking classes IA or III antiarrhythmic agents (quinidine, procainamide, amiodarone,
             sotalol), cisapride, erythromycin, perphenazine/amitriptyline, phenothiazines, or
             tricyclic antidepressant

          -  Diseases or conditions for which treatment with other drugs with antituberculosis
             activity (e.g., rifabutin for MAC prophylaxis) is anticipated during the course of the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E. Chaisson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clementino Fraga Filho Hospital</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2004</study_first_submitted>
  <study_first_submitted_qc>May 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2004</study_first_posted>
  <results_first_submitted>March 26, 2013</results_first_submitted>
  <results_first_submitted_qc>March 26, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2013</results_first_posted>
  <last_update_submitted>March 26, 2013</last_update_submitted>
  <last_update_submitted_qc>March 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2013</last_update_posted>
  <responsible_party>
    <name_title>Dr. Richard E. Chaisson</name_title>
    <organization>Johns Hopkins University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects with respiratory symptoms suggestive of TB were recruited from the HUCFF outpatient TB clinic as well as other local TB clinics.</recruitment_details>
      <pre_assignment_details>Patients who did not meet enrollment criteria or who did not want to participate in the study were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental Arm</title>
          <description>INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Culture negative or resistant at baselin</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>125 had 8-week data (moxifloxacin n=64, ethambutol n=61)</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental Arm (Moxi)</title>
        </group>
        <group group_id="B2">
          <title>Control Arm (EMB)</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="11.7"/>
                    <measurement group_id="B2" value="35.7" spread="12.0"/>
                    <measurement group_id="B3" value="34.1" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Sterile Sputum Cultures</title>
        <description>Proportion of patients with sterile sputum cultures</description>
        <time_frame>8 weeks</time_frame>
        <population>Proportion of patients with sterile sputum cultures at week 8</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Sterile Sputum Cultures</title>
          <description>Proportion of patients with sterile sputum cultures</description>
          <population>Proportion of patients with sterile sputum cultures at week 8</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications</title>
        <description>Proportion of patients with Grade 3 or 4 adverse reactions attributable to study medications</description>
        <time_frame>8 weeks</time_frame>
        <population>DAIDS Table of Adverse Events</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications</title>
          <description>Proportion of patients with Grade 3 or 4 adverse reactions attributable to study medications</description>
          <population>DAIDS Table of Adverse Events</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental Arm</title>
          <description>INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>DAIDS Toxicity Table</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Causes of deaths in the study included: sepsis, gunshots, neoplasm, intracranial hemorrhage, PTB and unknown, none related to study medications</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Hospitalization AEs for this study included:Community acquired pneumonia, abscess, D&amp;C, edema and polyneuropathy, none related to study drugs</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 4 event</sub_title>
                <description>Proteinuria, judged to be not related to study drugs</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard Chaisson</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-955-1755</phone>
      <email>rchaiss@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

